[Diagnostic contribution of HBME-1 and anti-cytokeratin-19 antibodies in thyroid pathology: a retrospective study of 163 cases].
The objective of our study was to estimate the expression of 2 antibodies HBME-1 and anti-cytokeratin-19 and their diagnostic importance in thyroid pathology.


METHODS
163 thyroid lesions were retrospectively examined by immnohistochemistry.


RESULTS
92% (46/50 cases) of papillary carcinomas expressed HBME-1 as well as 50% (8/16 cases) of follicular carcinomas and 15% (6/40 cases) of follicular adenomas. 8 insular carcinomas, 5 anaplastic carcinomas, 20 cases of Basedow disease and lymphocytic thyroiditis, and the 24 cases of nodular goiters did not express it or very focally. Anti-cytokératine-19 marked 92% of papillary carcinomas, 56.2% of follicular carcinomas, 100% of the medullar carcinomas and 45% of follicular adenomas. Whereas the cases of anaplastic carcinomas, Basedow disease, thyroiditis and the cases of nodular goiters were negative or focally marked.


CONCLUSIONS
HBME-1 is an excellent marker for papillary carcinoma which can be helpful in the diagnosis of its follicular variant; the association with anti-cytokératine-19 increases its specificity.
Ziadi
Sonia
S
Laboratoire d'Anatomie et de Cytologie Pathologique, CHU Farhat Hached de Sousse.
Trimeche
Mounir
M
Zermani
Rachida
R
Elmay
Ahmed
A
Baltagi-Ben Jilani
Sarrah
S
D000906:Antibodies; D015415:Biomarkers / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000276:immunology*; D003937:Diagnosis, Differential; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000032:analysis* / Q000276:immunology*; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D013959:Thyroid Diseases / Q000175:diagnosis* / Q000276:immunology; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000276:immunology; D000951:Antigens, Neoplasm
D000906:Antibodies; D015415:Biomarkers; D014408:Biomarkers, Tumor; D007633:Keratins; C432845:HBME-1 antigen; D000951:Antigens, Neoplasm